Study On A Novel Recombinant Immunotoxin DT390-IP10 And Its Treating Effects On Experimental Allergic Encephalomyelitis

Objective Experimental autoimmune encephalomyelitis (EAE) is a Th1 cell mediated demyelinating disease of the central nervous system (CNS) and serves as a well-established animal model for the human autoimmune disease multiple sclerosis (MS). According to the widely accepted view of the pathogenetic process of EAE and MS, activated T cells migrated to the CNS and developed inflammatory lesion. Moreover, it is well known that directional movement of lymphocytes in any aspect of their activities such as development, homeostatic circulation and inflammatory response are directed by chemokines associated surface chemokine receptors on lymphocytes and more recently evidence has accumulated that chemokines and their receptors preferentially expressed in T cells are involved in the pathogenesis of EAE and MS. Among these receptors, CXCR3 selectively expressing in encephalitogenic T cells are essential for the T cell recruitment to the inflammatory . CXCL10/IP-10 (interferon-g inducible protein-10) in CSF is significantly higher in MS than in controls, and the type 1 helper T (Th1) cells expressing CXCR3, the receptor of CXCL10/IP-10, are infiltrated in the brain and CSF in MS. Therefore, CXCR3 , overexpressed in the specific activated T cells membrance would be used as a specific surface marker to identify the encephalitogenic T cells and target killing of the cells for treating EAE with as...